Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Essen Biotech
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07410676CT.gov EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04901741CT.gov Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer | — | Not Yet Recruiting | — | — | — |
NCT06381154CT.gov Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT06378047CT.gov Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT05187338CT.gov Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04753879CT.gov Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | — | Active Not Recruiting | — | — | — |
NCT04887805CT.gov Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04835402CT.gov Electroporation Potentiated Immunotherapy in Cancer | — | Unknown | — | — | — |
NCT04548752CT.gov Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | — | Active Not Recruiting | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
Show 18 more trialsShow fewer
NCT04429542CT.gov Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04058964CT.gov Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | — | Withdrawn | — | — | — |
NCT02757391CT.gov CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | — | Terminated | — | — | — |
NCT03432676CT.gov Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | — | Withdrawn | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03681951CT.gov First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03723915CT.gov Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | — | Terminated | — | — | — |
NCT03621982CT.gov Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03331562CT.gov A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | — | Completed | — | — | — |
NCT03264404CT.gov Azacitidine and Pembrolizumab in Pancreatic Cancer | — | Completed | — | — | — |
NCT03095781CT.gov Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | — | Completed | — | — | — |
NCT03168139CT.gov Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer | — | Completed | — | — | — |
NCT02930902CT.gov Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery | — | Completed | — | — | — |
NCT02907099CT.gov Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT02600949CT.gov Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | — | Enrolling By Invitation | — | — | — |
NCT02362048CT.gov ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT01174121CT.gov Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Essen Biotech | P2 | BB · 66 |
| Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer | Chinese PLA General Hospital | P4 | BBB |
| Metformin | State University of New York - Downstate Medical Center | P2 | BBB |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Jonsson Comprehensive Cancer Center | P2/3 | BB |
| Olaparib | MOMA Therapeutics | P2 | BB |
| Tunlametinib | Chinese PLA General Hospital | P4 | BB |
+42 more in the Malignant Pancreatic Neoplasm cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, DimerChinese PLA General HospitalBBB
- MetforminState University of New York - Downstate Medical CenterBBB
- FluorouracilumJonsson Comprehensive Cancer CenterBBB
- IrinotecanJonsson Comprehensive Cancer CenterBB
- OxaliplatinJonsson Comprehensive Cancer CenterBB
Citation
Floatz Terminal. Pembrolizumab in Malignant Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-malignant-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →